


### **Abnormal Uterine Bleeding (AUB)**

**Emergency Department** 

Center for Clinical Excellence



CPP-ED Abnormal Uterine Bleeding Clinical Pathway Published: 6/19/2024; Last Revised: 6/19/2024

# **Definition & Diagnosis**

In clinical practice, the diagnosis, evaluation and treatment of heavy bleeding are based upon "patient experience", the female's personal assessment of blood loss and its impact on her life.

Matteson et al. Non-surgical management of heavy menstrual bleeding: a systematic review and practice guidelines. Obstet Gynecol 2013;121:632-643

### **General Guidelines for Consideration**

### Normal menstrual bleeding:

- Cycle length 21-45 days
- Flow length < 7 days
- Product (pad or tampon) use ≤ 6 products in 24 hours

### Heavy Menstrual bleeding:

Excessive menstrual loss that interferes with the patient's physical, emotional, social and material quality of life and can occur alone or in combination with other symptoms

F. Haamid et al. Heavy Menstrual Bleeding in Adolescents. NASPAG Committee Opinion. J Pediatr Adolsc Gynecol. 2017;30:335-340



# Focused History for Evaluation of Heavy Menstrual Bleeding

#### Bleeding pattern

- Frequency of changing pads or tampons
- Presence of clots > size of quarter
- o Effect on quality of life

### Symptoms of anemia

- Shortness of breath
- o Acute increase in exercise intolerance
- o Lightheadedness
- o Syncope
- Sexual and reproductive history
  - o Menstrual history
  - Possibility of current pregnancy
  - o Contraceptives use
  - o Sexually transmitted infections

### Associated symptoms

- o Fever
- o Chills
- Pelvic pressure or pain
- o Bowel or bladder dysfunction
- o Vaginal discharge or odor
- Symptoms associated with systemic cause
  - o Obesity
  - o PCOS
  - o Hypothyroidism
  - o Hyperprolactinemia,
  - o Hypothalamic or adrenal disorder

#### Chronic medical illness

- o Inherited bleeding disorders (coagulopathy, blood dyscrasias, platelet function disorders)
- o Systemic lupus erythematosus or other connective tissue diseases
- $\circ$   $\;$  Liver disease, renal disease, cardiovascular disease
- Medications
  - o Hormonal contraceptives
  - o Anticoagulants

### Family history

- o Coagulation or thromboembolic disorders
- Hormone-sensitive cancers

### **Estrogen contraindications**

- Relative contraindication:
  - First degree relative with history of PE or DVT
- Absolute contraindications:
  - o Current or past blood clot
  - Current or past migraine + aura
  - Hypertension (Systolic > 140, diastolic > 90)
  - Systemic lupus erythematosus with + lupus anticoagulant
  - Thrombotic mutations: prothrombin mutation, factor V Leiden
  - Protein C, Protein S and antithrombin deficiencies
  - Estrogen-dependent tumors
  - Hepatic dysfunction or disease

### Adapted from:

F. Haamid et al. Heavy Menstrual Bleeding in Adolescents. NASPAG Committee Opinion. J Pediatr Adolsc Gynecol. 2017;30:335-340



## **Differential Diagnoses**

### • Endocrine

- o Anovulatory bleeding
- Polycystic ovarian syndrome
- o Thyroid disease
- Bleeding disorders
  - $\circ~$  Von Willebrand disease
  - o Platelet dysfunction
  - o Thrombocytopenia
  - Clotting factor deficiency
- Pregnancy
  - $\circ$  Abortion
  - o Ectopic pregnancy
  - o Gestational trophoblastic disease

### • Infection

- Sexually transmitted diseases Gonorrhea/Chlamydia/Trichomonas
- $\circ$  Adenomyosis

### Uterine

- o Myoma
- o Intrauterine device
- o Polyp
- Cancer

### • Medication

- o Depot medroxyprogesterone
- o Anticoagulants

### • Other

- o Trauma
- o Foreign body
- Hemorrhagic ovarian cysts

F. Haamid et al. Heavy Menstrual Bleeding in Adolescents. NASPAG Committee Opinion. J Pediatr Adolsc Gynecol. 2017;30:335-340

### **Concern for Bleeding Disorder**

Laboratory evaluation for a bleeding disorder occurs during follow-up with Adolescent Medicine

Among adolescents with heavy menstrual bleeding, up to 20% are reported to have an underlying bleeding disorder with the following suggested frequencies:

- Von Willebrand disease 5-36%
- Platelet function defects 2-44%
- Thrombocytopenia 13-20%
- Clotting factor deficiencies 8-9%

### Possible bleeding disorder if any of the following:

- Saturating a product faster than every 2 hours
- Clots bigger than a quarter
- Needing 2 products at once
- Frequent "accidents" or leaking through protection
- "Flooding" sensation
- · Previous or current diagnosis of anemia
- Excessive bleeding with tooth extraction, surgery
- Family history of diagnosed bleeding disorder

F. Haamid et al. Heavy Menstrual Bleeding in Adolescents. NASPAG Committee Opinion. J Pediatr Adolsc Gynecol. 2017;30:335-340




# Symptomatic Anemia with AUB


### Symptoms of symptomatic anemia with AUB include:

- Shortness of breath
- Sustained tachycardia
- Difficulty with activities of daily living
- Orthostatic hypotension (fall of systolic BP over 20 mm Hg or fall in diastolic BP over 10 mm Hg within 3 minutes of standing)


### **Mild Bleeding Discharge Plan**




## **Moderate Bleeding Discharge Plan**



## **Severe Bleeding Discharge Plan**



## **Severe Bleeding Admission Plan**



# Indications for Admission to Pediatric Intensive Care

- Hemodynamically unstable patients should be admitted to the Pediatric Intensive Care Unit with Hematology consult
- Otherwise, call the Adolescent Medicine Fellow on call to discuss appropriateness of admission to Adolescent service



### Monophasic oral contraceptive pill (OCP) containing 30-50 mcg of estrogen:

- Norgestimate 0.25 mg/ethinyl estradiol 35 mcg (Sprintec, Mononessa, Ortho Cyclen)
- Norgestrel 0.3 mg/ethinyl estradiol 30mcg (Lo/Ovral\*, Low-Ogestrel, Cryselle)
- Levonorgestrel 0.15 mg/ethinyl estradiol 30mcg (Nordette, Levlen, Levora, Portia)

All are equally efficacious and well tolerated \*Used most often

#### **Estrogen contraindications**

- Relative contraindication (okay to use initially to control bleeding):
  - $\circ~$  First degree relative with history of PE or DVT
  - Absolute contraindications:
    - o Current or past blood clot
    - Current or past migraine + aura
    - Hypertension (Systolic > 140, diastolic > 90)
    - o Systemic lupus erythematosus with + lupus anticoagulant
    - Thrombotic mutations: prothrombin mutation, factor V Leiden
    - o Protein C, Protein S and antithrombin deficiencies
    - o Estrogen-dependent tumors
    - Hepatic dysfunction or disease

#### Progestin-only alternatives:

- Norethindrone acetate (Aygestin) 5 mg
- Medroxyprogesterone acetate (Provera) 10 mg

Counsel patient that these are not birth control pills and not FDA approved for contraception

### Estrogen-containing medications and Progestin-only alternatives can be tapered the same way:

- Moderate bleeding
  - o Initiate hormone therapy with one pill twice per day until bleeding stops
  - Then one pill per day for 21 days

#### • Severe bleeding:

- One hormone pill four times per day for 2-4 days (duration to be determined at follow-up)
- $\circ~$  THEN one hormone pill three times per day for 3 days
- THEN one hormone pill twice a day for at least 2 weeks

#### **Estrogen IV:**

#### Conjugated estrogen 25 mg Q6

Slow push over 5 minutes. If flushing occurs, decrease rate by 50%. (Lexicomp®)

### **Oral Iron Supplementation:**

Ferrous sulfate 325 mg (65 mg elemental iron) once daily for patients who are  $\geq$  35 kg (Otherwise 3-6 mg/kg of elemental iron once daily with a max of 100 mg elemental iron daily if < 35 kg)

### **Metrics**

#### **Pathway Goal**

To provide a standardized approach to evaluation and treatment of abnormal uterine bleeding in nonpregnant patients.

#### **Quality Measures**

#### **Outcome Metrics**

• Iron supplementation provided for patients with abnormal uterine bleeding and hemoglobin < 11 g/dL

#### **Process Metrics**

- Pathway Utilization
- Pathway visualization

### References

- Haamid F, Sass AE, Dietrich JE. Heavy menstrual bleeding in adolescents. J Pediatr Adolesc Gynecol. 2017;30(3):335-340. doi:10.1016/j.jpag.2017.01.002. Epub 2017 Jan 17. Erratum in: J Pediatr Adolesc Gynecol. 2017;30(6):665. PMID: 28108214.
- Huguelet PS, Buyers EM, Lange-Liss JH, Scott SM. Treatment of acute abnormal uterine bleeding in adolescents: what are providers doing in various specialties? *J Pediatr Adolesc Gynecol*. 2016;29(3):286-291. doi:10.1016/j.jpag.2015.10.021. Epub 2015 Nov 25. PMID: 26612118.
- Wouk N, Helton M. Abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2019;99(7):435-443. PMID: 30932448.
- Yaşa C, Güngör Uğurlucan F. Approach to abnormal uterine bleeding in adolescents. *J Clin Res Pediatr Endocrinol.* 2020;12(Suppl 1):1-6. doi:10.4274/jcrpe.galenos.2019.2019.S0200. PMID: 32041387; PMCID: PMC7053441.
- Matteson KA, Rahn DD, Wheeler TL, et al. Non-surgical management of heavy menstrual bleeding: a systematic review and practice guidelines. *Obstet Gynecol.* 2013;121:632-643.
- Bennett AR, Gray SH. What to do when she's bleeding through: the recognition, evaluation, and management of abnormal uterine bleeding in adolescents. *Curr Opin Pediatr*. 2014;26(4):413-419. doi:10.1097/MOP.00000000000121. PMID: 25007322.
- Kanagasabai P, Suganthini P, et al. Interventions to improve access to care for abnormal uterine bleeding: a systematic scoping review. *Int J Gynecol Obstet*. 2023;160(1):38-48.
- Close AG, et al. Improving the evaluation and management of abnormal uterine bleeding in female adolescents presenting for emergency care. *J Pediatr Adolesc Gynecol*. 2019;32(2):128-134.
- Mullins ES, Miller RJ, Kowalczyk Mullins TL. Abnormal uterine bleeding in adolescent women. *Curr Pediatr Rep.* 2018;6:123-131.
- Levy-Zauberman Y, et al. Update on the management of abnormal uterine bleeding. *J Gynecol Obstet Hum Reprod*. 2017;46(8):613-622.
- O'Brien SH. Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist. In: American Society of Hematology. 2018:390-398.
- Mansour D, Hofman A, Gemzell-Danielsson K. A review of clinical guidelines on the management of iron deficiency and iron deficiency anemia in women with heavy menstrual bleeding. *Adv Ther*. 2021;38:201-225.

### Pathway Team & Process

**Clinical Pathways Program:** 

#### **Content Development Team:**

		Medical Director – Emergency Medicine:	
Leaders:			Berkeley Bennett, MD, MS
Emergency Medicine:		Medical Director – Clini	cal Informatics & Emergency Medicine: Laura Rust, MD, MPH
	Abha Athale, MD Berkeley Bennett, MD, MS	Physician Informatics:	
Adolescent Medicine:			Kathy Nuss, MD
	Kristen Reilly, MD, MSW	Business & Development Manager: Rekha Voruganti, MBOE, LSSBB	
Members:		Program Coordinators:	
Hematology:	Amanda Jabocson-Kelly, MD, MSc	-	Tahje Brown, MBA Tara Dinh, BS
Vilmarie Rodriguez, MD		Clinical Pathway Approved:	
Emergency Medicine:	Jenny Steinbrenner, PharmD, BCPPS	Medical Director - Associate Chief Quality Officer, Center for	
Emergency Services:		Clinical Excellence:	Dura Dada MD MDOF
	Kelli Mavromatis, RN, BSN, CPEn Barbara Abdalla, RN, MSN, CPN		Ryan Bode, MD, MBOE
Adolescent Medicine:	Fareeda Haamid, MD	Advisory Committee: June, 2024	
	Cynthia Holland-Hall, MD, MPH	Origination Date: June, 2024	
Gynecology:	Chelsea Kebodeaux, MD	Next Revision Date: June, 2027	

#### **Clinical Pathway Development**

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associates with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

#### For more information about our pathways and program please contact: ClinicalPathways@NationwideChildrens.org

